The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | The transformative role of BTK inhibition in CLL: from ibrutinib to next-generation therapies
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses the central role of BTK in the pathophysiology of chronic lymphocytic leukemia (CLL), highlighting how BTK inhibitors (BTKis) have transformed patient outcomes. She outlines the evolution from first-generation ibrutinib to the better-tolerated second-generation agents and discusses the potential of pirtobrutinib for patients who develop resistance to covalent BTKis. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
